top of page
Kicking Cancer's KRAS Expert Series with Dr. Tanios Bekaii-Saab
Kicking Cancer's KRAS Expert Series with Dr. Tanios Bekaii-Saab

Tue, Mar 01

|

Virtual/Live

Kicking Cancer's KRAS Expert Series with Dr. Tanios Bekaii-Saab

Tanios Bekaii-Saab, M.D., FACP, Leader of the Gastrointestinal Cancer Program, and Director of the Clinical Cancer Research Office for the Enterprise wide Mayo Clinic Cancer Center will be joining us to discuss the latest in research and treatments for patients with gastrointestinal cancers.

Registration is Closed
See other events

Time & Location

Mar 01, 2022, 2:30 PM – 4:00 PM EST

Virtual/Live

About the Event

We are very excited to welcome Tanios Bekaii-Saab, M.D., FACP, to the Kicking Cancer's KRAS Expert Series! Dr. Bekaii-Saab is a Professor of Medicine at the Mayo Clinic College of Medicine and Science, Leader of the Gastrointestinal Cancer Program, and Director of the Clinical Cancer Research Office for the Enterprise wide Mayo Clinic Cancer Center. He is also the Vice Chair and Section Chief for Medical Oncology for the Division of Hematology/Oncology in the Department of Internal Medicine at the Mayo Clinic in Phoenix, Arizona, USA.

Dr. Bekaii-Saab conducts clinical and translational research focused on developing anticancer agents for patients with gastrointestinal cancers. He collaborates extensively with various scientists and industry partners to design and execute innovative clinical trials, including many first-in-human studies. His research includes a large focus on the incorporation of agents that target the multiple facets of cancer, including genetic and epigenetic drivers, as well as the feeding microenvironment and the immune milieu. Additionally, Dr. Bekaii-Saab’s research has also led to the launch of a number of phase II and III clinical trials, including but not limited to a recent trial with a cancer stem cell inhibitor in pancreatic cancer, the development of an FGFR inhibitor in bile duct cancers including a contribution to the regulatory approval of infigratinib and pemigatinib. 

Learn more about Dr. Bekaii-Saab here.

This event has a group. You’re welcome to join the group once you register for the event.

Share This Event

bottom of page